SOLICITATION NOTICE
65 -- Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
- Notice Date
- 7/29/2025 8:26:11 AM
- Notice Type
- Solicitation
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- DEFENSE HEALTH AGENCY AURORA CO 80011 USA
- ZIP Code
- 80011
- Solicitation Number
- HT9402-25-Q-9401
- Response Due
- 9/22/2025 10:00:00 AM
- Archive Date
- 01/24/2026
- Point of Contact
- Stephanie Erpelding, Julia Trang
- E-Mail Address
-
stephanie.j.erpelding.civ@health.mil, julia.n.trang.civ@health.mil
(stephanie.j.erpelding.civ@health.mil, julia.n.trang.civ@health.mil)
- Description
- The Department of Defense (DoD) is required by law (10 U.S.C. � 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. a. Class Insulins, Subclass Rapid Acting Agents U-100 Admelog Apidra Fiasp Humalog Insulin Aspart Insulin Lispro Lyumjev Novolog Merilog b. Class Insulins, Subclass Rapid Acting Agents U-200 Lyumjev Kwikpen U-200 Humalog Kwikpen U-200 c. Class Metabolic Dysfunction Agents, Subclass Injectable Diabetic Agents Bydureon Bcise Byetta Exenatide Mounjaro Ozempic Semaglutide Tirzepatide Trulicity d. Class Metabolic Dysfunction Agents, Subclass Injectable Weight Loss Agents Saxenda Wegovy Zepbound The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9401. Pre-quotation teleconference is on July 30, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/dcb104a0eae54362b2b5795e1e989ad7/view)
- Record
- SN07528833-F 20250731/250729230104 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |